Q-omics provides the consensus-scored SMIM1 profile across patient tissues and cancer cell-line models. SMIM1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SMIM1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SMIM1 RNA expression shows 15,823 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, THCA, and THYM as cancer lineages where SMIM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM1 survival associations across molecular data types. SMIM1 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM1 RNA expression–survival associations across cancer types. High SMIM1 expression shows unfavorable associations in UCEC, LUSC, CESC and DLBC, but favorable associations in UVM and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SMIM1 RNA expression.
This table summarizes SMIM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMIM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM1 shows lower tumor expression in KICH, LUSC and CHOL and higher tumor expression in THCA, COAD and BRCA. The THCA box plot shows higher SMIM1 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with SMIM1 in patient tissues and cancer cell lines. In patient samples, SMIM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
